BioWorld

Aug. 28, 2008

Direct Reprogramming Is New Cell Source for Regeneration

NexMed Shares Fall Hard as Novartis Nixes NDA

Other News To Note

Clinic Roundup

Cell Genesys Falls 70% as Patient Deaths Derail GVAX Phase III

In yet another setback for cancer vaccines, Cell Genesys Inc. terminated one of its two Phase III trials with prostate cancer vaccine GVAX. (BioWorld Today) Read More

Amylin Sinks on Further Byetta Worries: More Deaths Reported

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

US lawmakers demand that Kennedy be held accountable

BioWorld

As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...